NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA135: Pemetrexed disodium for the treatment of mesothelioma

This guidance was issued January, 2008 with a review date of September 2010.

Background

At the GE meeting [28 September] it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to	The guidance should be transferred to the 'static guidance' list
consultees:	

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation	The guidance should be transferred to the 'static guidance' list
post	
consultation:	

Respondent	Response to proposal	Details	Comment from Technology Appraisal
Bristol-Myers Squibb	Agree		
Pharmaceuticals (cisplatin)			
British Thoracic Society	Agree		
Eli Lilly	Agree		
Medicines and Healthcare	Agree		
products Regulatory			
Agency			
NHS Camden	Agree		
NHS Quality Improvement	No comment		
Scotland			
Public Health Wales NHS	Agree		
Trust			
Royal College of Nursing	Agree		
Royal College of Physicians	Agree		
Welsh Assembly	No comment		
Government			

No response received from:

Patient/carer groups	<u>General</u>
Afiya Trust	 Board of Community Health Councils in Wales
Black Health Agency	British National Formulary
British Lung Foundation	Care Quality Commission
CANCERactive	 Commissioning Support Appraisals Service
Cancer Black Care	 Department of Health, Social Services and Public
Cancer Equality	Safety for Northern Ireland
 Chinese National Healthy Living Centre 	 National Association of Primary Care
Counsel and Care	NHS Alliance
Equalities National Council	 NHS Commercial Medicines Unit

- Helen Rollason Heal Cancer Charity
- Macmillan Cancer Support
- Maggie's Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- Muslim Health Network
- Roy Castle Lung Cancer Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sue Ryder Care
- Tenovus
- United Kingdom Lung Cancer Coalition

Professional groups

- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- British Association for Services to the Elderly
- British Geriatrics Society
- British Oncological Association
- British Psychosocial Oncology Society
- Cancer Network Pharmacists Forum
- Cancer Research UK
- National Lung Cancer Forum for Nurses
- Primary Care Respiratory Society UK
- Royal College of General Practitioners
- Royal College of Pathologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

- NHS Confederation
- Public Health Wales NHS Trust
- Scottish Medicines Consortium

Comparator manufacturers

- Actavis UK (vinorelbine)
- Genus Pharmaceuticals (vinblastine)
- Goldshield (cisplatin)
- Hospira UK (cisplatin, vinblastine, vinorelbine)
- Kyowa Hakko Kirin (mitomycin c)
- Medac (venorelbine)
- Pfizer (cisplatin)
- Pierre Fabre (vinorelbine)
- Wockhardt UK (cisplatin, vinorelbine)

Relevant research groups

- British Thoracic Oncology Group
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Policy Research Institute on Ageing and Ethnicity
- Research Institute for the Care of Older People

Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme
- Associated Guideline Groups

Others	National Collaborating Centre for Cancer	
Department of Health	Associated Public Health Groups	
NHS North Lincolnshire	None	l

GE paper sign-off: Helen Chung 29 November 2010

Contributors to this paper:

Technical Lead: Chris Griffiths Technical Adviser: Zoe Charles Project Manager: Andrew Harding